Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
You may also be interested in...
Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.
Bristol Says It’s Ready For PD-1 Competition In Lung Cancer
Opdivo sales got out of the gate slowly, but Bristol sees encouraging trends – and has a validated diagnostic for the PD-L1 therapy at the ready, if needed.
Bristol Keeps Focus On Opdivo In Lung Cancer
Now that the PD-1 inhibitor has a melanoma approval under its belt, Bristol-Myers is moving full steam ahead with the development of Opdivo with 11 lung cancer clinical trials ongoing or planned.